Using interactive platforms to encode, manage and explore immune-related adverse outcome pathways
暂无分享,去创建一个
A. Mazein | V. Satagopam | Z. Waibler | M. Ostaszewski | K. Reiche | Wei Gu | S. Schiffmann | K. Sewald | V. Neuhaus | Patricia Gogesch | Muhammad Shoaib | R. Schneider | Charline Sommer | C. Sakellariou | M. Alb | Luise A Roser | Susann Dehmel | Samira Ortega Iannazzo | Sapna Sheth | Reinhard Schneider
[1] Alexander R. Pico,et al. COVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms , 2021, Molecular systems biology.
[2] Ugur Dogrusoz,et al. Newt: a comprehensive web-based tool for viewing, constructing and analyzing biological maps , 2020, Bioinform..
[3] Marek Ostaszewski,et al. Reusability and composability in process description maps: RAS–RAF–MEK–ERK signalling , 2020, bioRxiv.
[4] Thomas S. Ligon,et al. AsthmaMap: an interactive knowledge repository for mechanisms of asthma. , 2020, The Journal of allergy and clinical immunology.
[5] Anna Niarakis,et al. Automated inference of Boolean models from molecular interaction maps using CaSQ , 2020, Bioinform..
[6] J. Myklebust,et al. Tuning the Antigen Density Requirement for CAR T Cell Activity. , 2020, Cancer discovery.
[7] Piotr Gawron,et al. RA-map: building a state-of-the-art interactive knowledge base for rheumatoid arthritis , 2020, Database J. Biol. Databases Curation.
[8] Marek Ostaszewski,et al. Closing the gap between formats for storing layout information in systems biology , 2019, Briefings Bioinform..
[9] C. Reinhardt,et al. Physiological Roles of the von Willebrand Factor-Factor VIII Interaction. , 2020, Sub-cellular biochemistry.
[10] J. Bergh,et al. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. , 2019, The oncologist.
[11] Piotr Gawron,et al. MINERVA API and plugins: opening molecular network analysis and visualization to the community , 2019, Bioinform..
[12] I. Flinn,et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. , 2019, The Lancet. Oncology.
[13] Victoria McGilligan,et al. New models of atherosclerosis and multi-drug therapeutic interventions , 2018, Bioinform..
[14] Marek Ostaszewski,et al. Community-driven roadmap for integrated disease maps , 2018, Briefings Bioinform..
[15] Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways , 2019 .
[16] Viktoriya Zvoda,et al. Construction and Data Analysis , 2018 .
[17] Craig W. Freyer. Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia , 2018, Journal of the advanced practitioner in oncology.
[18] C. Auffray,et al. Systems medicine disease maps: community-driven comprehensive representation of disease mechanisms , 2018, npj Systems Biology and Applications.
[19] M. Sadelain,et al. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.
[20] Inna Kuperstein,et al. Signalling maps in cancer research: construction and data analysis , 2018, Database J. Biol. Databases Curation.
[21] David S. Wishart,et al. DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..
[22] John Kunze,et al. Uniform resolution of compact identifiers for biomedical data , 2017, Scientific Data.
[23] Inna Kuperstein,et al. Application of Atlas of Cancer Signalling Network in pre-clinical studies , 2017, bioRxiv.
[24] K. Mansfield,et al. Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights. , 2017, Blood.
[25] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[26] S. H. Bennekou,et al. Adverse outcome pathways: opportunities, limitations and open questions , 2017, Archives of Toxicology.
[27] D. Teachey,et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. , 2017, Cytotherapy.
[28] Piotr Gawron,et al. MINERVA—a platform for visualization and curation of molecular interaction networks , 2016, npj Systems Biology and Applications.
[29] Sharon Munn,et al. Adverse outcome pathway development from protein alkylation to liver fibrosis , 2016, Archives of Toxicology.
[30] G. Wertheim,et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. , 2016, Cancer discovery.
[31] Denis Thieffry,et al. Logical Modeling and Dynamical Analysis of Cellular Networks , 2016, Front. Genet..
[32] M. Wurfel,et al. Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness , 2015, PloS one.
[33] E. Barillot,et al. Atlas of Cancer Signalling Network: a systems biology resource for integrative analysis of cancer data with Google Maps , 2015, Oncogenesis.
[34] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[35] S. Riddell,et al. The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity , 2014, Cancer Immunology Research.
[36] D. Teachey,et al. Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies , 2014, Cancer journal.
[37] Hong Wang,et al. An evolving new paradigm: endothelial cells – conditional innate immune cells , 2013, Journal of Hematology & Oncology.
[38] H. Kitano,et al. Integrating Pathways of Parkinson's Disease in a Molecular Interaction Map , 2013, Molecular Neurobiology.
[39] T. Helikar,et al. A Cell Simulator Platform: The Cell Collective , 2013, Clinical pharmacology and therapeutics.
[40] Michel Sadelain,et al. The basic principles of chimeric antigen receptor design. , 2013, Cancer discovery.
[41] Alex Madrahimov,et al. The Cell Collective: Toward an open and collaborative approach to systems biology , 2012, BMC Systems Biology.
[42] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[43] Falk Schreiber,et al. Editing, validating and translating of SBGN maps , 2010, Bioinform..
[44] M. Sadelain,et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[45] Daniel L Villeneuve,et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment , 2010, Environmental toxicology and chemistry.
[46] Sarala M. Wimalaratne,et al. The Systems Biology Graphical Notation , 2009, Nature Biotechnology.
[47] Hugh D. Spence,et al. Minimum information requested in the annotation of biochemical models (MIRIAM) , 2005, Nature Biotechnology.
[48] C. Wouters,et al. Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. , 2005, Blood.
[49] Hiroaki Kitano,et al. The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..